This study is testing a new way to treat aortic aneurysms (a bulging in the body's main artery) that involve major arteries to your organs. It uses a device called the Zenith® Fenestrated+ Endovascular Graft, along with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2. The study aims to see how safe and effective this treatment is. You might be able to join if you have a specific type of aortic aneurysm that is at least 55mm (for males) or 50mm (for females), or if it's growing quickly, or is more than twice the normal size. Researchers will measure if the device works as intended and is safe after 30 days, and if it prevents aneurysm-related deaths and serious re-interventions after 12 months. The study plans to enroll 105 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 105 participants, with up to 60 more in a continued access phase.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Researchers will follow participants for at least 12 months after the procedure to assess long-term safety and effectiveness.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.